Kazuhiko Morii
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kazuhiko Morii has a total of 66 co-authors. Here are the top co-authors by number of shared publications:
Hiroaki Okushin
Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan
12 shared publicationsShinichiro Nakamura
Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan
11 shared publicationsTakeharu Yamamoto
Department of Hepatology, Japanese Red Cross Society Himeji Hospital, Japan
11 shared publications- Hiroaki Okushin
Department of Hepatology, Japanese Red Cross Society Himeji Hospital, 1-12-1 Shimoteno, Himeji, Hyogo 670-8540, Japan
6 shared publications Shiro Yuasa
Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Japan
6 shared publicationsKoichi Uesaka
Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan
5 shared publications
Latest Publications
- Open Access
- 8 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7577
Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology
Background and aim: We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods: A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. We defined the following areas of the liver as those where MTA therapy is difficult to perform: caudate lobe and areas near the primary and secondary branches of the intrahepatic portal vein, inferior vena cava, gallbladder, heart, duodenum, abdominal esophagus, collateral veins around the liver, and spleen. Factors which predisposed patients to local tumor recurrence in the context of tumor location and complications were examined. Results: The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: 6.6%, 13.8%, and 29.4% at three years in the ≤20 mm group (n = 483), 20–30 mm group (n = 107), and ≥30 mm group (n = 17), respectively (p < 0.001). The cumulative local tumor recurrence rate was similar despite difficult-to-treat status (p = 0.169). In the multivariable analysis, tumor size (>15 mm) (hazard ratio [HR], 2.15; 95% confidence interval [CI], 1.11–4.16; p = 0.023) and ablative margin (15 mm) (odds ratio, 3.41 95% CI, 1.53–7.84; p = 0.026) was significantly associated with complications. Conclusions: MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.
- 8 December 2023
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 12 (24) , 7577
Open AccessClinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology
Background and aim: We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods: A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. We defined the following areas of the liver as those where MTA therapy is difficult to perform: caudate lobe and areas near the primary and secondary branches of the intrahepatic portal vein, inferior vena cava, gallbladder, heart, duodenum, abdominal esophagus, collateral veins around the liver, and spleen. Factors which predisposed patients to local tumor recurrence in the context of tumor location and complications were examined. Results: The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: 6.6%, 13.8%, and 29.4% at three years in the ≤20 mm group (n = 483), 20–30 mm group (n = 107), and ≥30 mm group (n = 17), respectively (p < 0.001). The cumulative local tumor recurrence rate was similar despite difficult-to-treat status (p = 0.169). In the multivariable analysis, tumor size (>15 mm) (hazard ratio [HR], 2.15; 95% confidence interval [CI], 1.11–4.16; p = 0.023) and ablative margin (15 mm) (odds ratio, 3.41 95% CI, 1.53–7.84; p = 0.026) was significantly associated with complications. Conclusions: MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.
- Open Access
- 26 October 2023
- Published by MDPI AG in Preprints.org
Clinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology
Background and aim We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. Results The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=483), 20–30 mm group (n=107), and ≥30 mm group (n=17) (p<0.001). The cumulative local tumor recurrence rate was similar by difficult-to-treat status (p=0.169). In the multivariable analysis, tumor size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p<0.001) and ablative margin (per 1 mm) (HR, 0.81; 95% CI, 0.70–0.92; p=0.002) were significantly associated with local tumor recurrence. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.02–1.15; p=0.015) was significantly associated with complications. Conclusions MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.
- 26 October 2023
- Published by MDPI AG in Preprints.org
Open AccessClinical Outcomes of Next-Generation Microwave Thermosphere Ablation for Hepatocellular Carcinoma with Primarily Hepatitis-Related Etiology
Background and aim We investigated the clinical outcomes of patients with hepatocellular carcinoma (HCC) who underwent next-generation microwave thermosphere ablation (MTA). Methods A total of 429 patients with 607 HCCs (maximum tumor diameter ≤40 mm) were included. Results The primary etiologies of HCC were hepatitis-related: 259 (60.4%) cases of HCV, 31 (7.3%) cases of HBV, and two instances of both. Median maximum tumor diameter was 15.0 (interquartile range, 10.0–21.0) mm. There were 86 tumors in areas of the liver where MTA is difficult. The most common area was near the primary and secondary branches of the intrahepatic portal vein (26 nodules). The cumulative local tumor recurrence rates at 1, 2, and 3 years were 4.4%, 8.0%, and 8.5%, respectively. The cumulative local tumor recurrence rate differed significantly by tumor size group: ≤20 mm group (n=483), 20–30 mm group (n=107), and ≥30 mm group (n=17) (p<0.001). The cumulative local tumor recurrence rate was similar by difficult-to-treat status (p=0.169). In the multivariable analysis, tumor size (per 1 mm) (hazard ratio [HR], 1.07; 95% confidence interval [CI], 1.03–1.11; p<0.001) and ablative margin (per 1 mm) (HR, 0.81; 95% CI, 0.70–0.92; p=0.002) were significantly associated with local tumor recurrence. Only tumor size (per 1 mm) (odds ratio, 1.08; 95% CI, 1.02–1.15; p=0.015) was significantly associated with complications. Conclusions MTA is a safe and effective local ablation therapy for HCC, even for tumors located in areas of the liver where local ablation therapy is difficult.
- Open Access
- 15 August 2019
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 58 (16) , 2417
Diffuse Reticulate Purpura
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 15 August 2019
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 58 (16) , 2417
Open AccessDiffuse Reticulate Purpura
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 15 December 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (24) , 3545-3549
Hepatocellular Carcinoma in a Patient with Hereditary Hemorrhagic Telangiectasia
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 15 December 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (24) , 3545-3549
Open AccessHepatocellular Carcinoma in a Patient with Hereditary Hemorrhagic Telangiectasia
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2271-2272
Streptococcus Anginosus Group-associated Pyogenic Liver Abscess
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2271-2272
Open AccessStreptococcus Anginosus Group-associated Pyogenic Liver Abscess
Japan's largest platform for academic e-journals: J-STAGE is a full text database for reviewed academic papers published by Japanese societies
- Open Access
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2123-2129
Infectious Hepatic Cyst: An Underestimated Complication
Objective An infectious hepatic cyst (IHC) is a hepatic cyst complicated with secondary infection and is generally assumed to be rare. However, we have experienced no small number of patients with IHC in recent clinical practice. We therefore examined the incidence and clinical characteristics of IHC. Methods The medical records of patients with IHC who were hospitalized at our institution between January 2012 and December 2016 were retrospectively reviewed. Their demographic factors, biochemical, bacteriological, imaging, and treatment results were explored and compared with those of patients with pyogenic liver abscess (PLA). Patients Twelve patients with IHC and 39 with PLA were identified. Results The IHCs were significantly larger in diameters than the PLAs, and patients with IHCs tended to be older and more often women than those with PLAs. IHCs showed characteristic imaging features, including heterogeneous contents with occasional fluid-debris levels, a thickened cystic wall with rim enhancement, perilesional edema and hyperaemia. Patients with IHCs had a significantly shorter hospital stay than those with PLAs. Conclusion Physicians should note that IHCs are not rare. A careful imaging evaluation can suggest an IHC, and the timely aspiration of the content can lead to an accurate diagnosis. The cystic wall may keep the infectious material confined within the IHC, resulting in the observed good treatment outcome with catheter drainage.
- 1 August 2018
- Published by Japanese Society of Internal Medicine in Internal Medicine
- Vol. 57 (15) , 2123-2129
Open AccessInfectious Hepatic Cyst: An Underestimated Complication
Objective An infectious hepatic cyst (IHC) is a hepatic cyst complicated with secondary infection and is generally assumed to be rare. However, we have experienced no small number of patients with IHC in recent clinical practice. We therefore examined the incidence and clinical characteristics of IHC. Methods The medical records of patients with IHC who were hospitalized at our institution between January 2012 and December 2016 were retrospectively reviewed. Their demographic factors, biochemical, bacteriological, imaging, and treatment results were explored and compared with those of patients with pyogenic liver abscess (PLA). Patients Twelve patients with IHC and 39 with PLA were identified. Results The IHCs were significantly larger in diameters than the PLAs, and patients with IHCs tended to be older and more often women than those with PLAs. IHCs showed characteristic imaging features, including heterogeneous contents with occasional fluid-debris levels, a thickened cystic wall with rim enhancement, perilesional edema and hyperaemia. Patients with IHCs had a significantly shorter hospital stay than those with PLAs. Conclusion Physicians should note that IHCs are not rare. A careful imaging evaluation can suggest an IHC, and the timely aspiration of the content can lead to an accurate diagnosis. The cystic wall may keep the infectious material confined within the IHC, resulting in the observed good treatment outcome with catheter drainage.
- Open Access
- 28 December 2017
- Published by MedCrave Group Kft. in Gastroenterology & Hepatology: Open Access
- Vol. 8 (3) , 1-7
Multilocular Pyogenic Liver Abscess with Poorly Liquefied Content: A Potential Therapeutic Concern
- 28 December 2017
- Published by MedCrave Group Kft. in Gastroenterology & Hepatology: Open Access
- Vol. 8 (3) , 1-7
Open AccessMultilocular Pyogenic Liver Abscess with Poorly Liquefied Content: A Potential Therapeutic Concern
- Open Access
- 31 December 2016
- Published by ClinMed International Library in Journal of Clinical Gastroenterology and Treatment
- Vol. 2 (4)
Portal Hypertension Does Not Preclude the Efficacy of Direct-acting Anti-Hepatitis C Viral Therapy
Totally, 113 patients were included in this study; 26 with CSPH and 87 without CSPH. HCV genotype 1b-infected patients were treated with either daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir. HCV genotype 2-infected patients were treated with sofosbuvir plus ribavirin. Sustained virological response (SVR) rates were equally good in patients with CSPH (96%) and in those without CSPH (93%). In patients who achieved SVR, prompt improvements in the hepatic function were observed. Recovery was more pronounced in patients with CSPH. There was no early treatment discontinuation and no hepatic decompensation.
- 31 December 2016
- Published by ClinMed International Library in Journal of Clinical Gastroenterology and Treatment
- Vol. 2 (4)
Open AccessPortal Hypertension Does Not Preclude the Efficacy of Direct-acting Anti-Hepatitis C Viral Therapy
Totally, 113 patients were included in this study; 26 with CSPH and 87 without CSPH. HCV genotype 1b-infected patients were treated with either daclatasvir plus asunaprevir or sofosbuvir plus ledipasvir. HCV genotype 2-infected patients were treated with sofosbuvir plus ribavirin. Sustained virological response (SVR) rates were equally good in patients with CSPH (96%) and in those without CSPH (93%). In patients who achieved SVR, prompt improvements in the hepatic function were observed. Recovery was more pronounced in patients with CSPH. There was no early treatment discontinuation and no hepatic decompensation.
- 17 August 2016
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (10) , 1722-1728
Increasing incidence of elderly‐onset autoimmune hepatitis
Aim: Autoimmune hepatitis (AIH) commonly shows bimodal distribution of onset age: at young adulthood and at 50–60 years‐of‐age. However, in recent times, the incidence of elderly‐onset AIH seems to be increasing. This study aimed to investigate whether the incidence of elderly‐onset AIH is increasing, and whether these patients show any clinical features different from those observed in younger patients.Methods: Data about patients with newly diagnosed AIH visiting the Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, were retrospectively collected for the period ranging from January 2010 to May 2016. A total of 71 patients (56 women and 15 men, age 18–88 years) were included in this study. Patients were divided into two cohorts: elderly (≥70 years; n = 28) and adult cohort (15–69 years; n = 43). Demographic and clinical characteristics, biochemical and serological markers, radiological and histological findings, and therapeutic courses were evaluated.Results: The median age of the patients was 65 years, the most frequent range being the 70s (37%), followed by the 60s (25%). The elderly cohort had significantly higher levels of serum immunoglobulin G and antinuclear antibody, lesser hepatitis activity scores, and lesser chance of developing other autoimmune diseases. They tended to have higher C‐reactive protein levels and lower serum alanine aminotransferase levels. All patients achieved clinical remission after treatment.Conclusions: This study clearly showed an increase in the incidence of elderly‐onset AIH. These patients had some unique characteristics, showing that the development of elderly‐onset AIH is influenced by age‐associated immune dysfunction called immunosenescence. Geriatr Gerontol Int 2017; 17: 1722–1728.
- 17 August 2016
- Published by Wiley in Geriatrics & Gerontology International
- Vol. 17 (10) , 1722-1728
Increasing incidence of elderly‐onset autoimmune hepatitis
Aim: Autoimmune hepatitis (AIH) commonly shows bimodal distribution of onset age: at young adulthood and at 50–60 years‐of‐age. However, in recent times, the incidence of elderly‐onset AIH seems to be increasing. This study aimed to investigate whether the incidence of elderly‐onset AIH is increasing, and whether these patients show any clinical features different from those observed in younger patients.Methods: Data about patients with newly diagnosed AIH visiting the Japanese Red Cross Society Himeji Hospital, Himeji, Hyogo, Japan, were retrospectively collected for the period ranging from January 2010 to May 2016. A total of 71 patients (56 women and 15 men, age 18–88 years) were included in this study. Patients were divided into two cohorts: elderly (≥70 years; n = 28) and adult cohort (15–69 years; n = 43). Demographic and clinical characteristics, biochemical and serological markers, radiological and histological findings, and therapeutic courses were evaluated.Results: The median age of the patients was 65 years, the most frequent range being the 70s (37%), followed by the 60s (25%). The elderly cohort had significantly higher levels of serum immunoglobulin G and antinuclear antibody, lesser hepatitis activity scores, and lesser chance of developing other autoimmune diseases. They tended to have higher C‐reactive protein levels and lower serum alanine aminotransferase levels. All patients achieved clinical remission after treatment.Conclusions: This study clearly showed an increase in the incidence of elderly‐onset AIH. These patients had some unique characteristics, showing that the development of elderly‐onset AIH is influenced by age‐associated immune dysfunction called immunosenescence. Geriatr Gerontol Int 2017; 17: 1722–1728.
- 7 July 2016
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (1) , e1
Dubin–Johnson Syndrome
Images in Clinical Medicine from The New England Journal of Medicine — Dubin–Johnson Syndrome
- 7 July 2016
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 375 (1) , e1
Dubin–Johnson Syndrome
Images in Clinical Medicine from The New England Journal of Medicine — Dubin–Johnson Syndrome